Login
Search
Search
0 Dates
2026
2025
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
CPC 2025
CPC 2026
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Genetic testing in patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM): high diagnostic yield in patients presenting with Heart Failure
Session:
Sessão de Posters 42 - Para além da hipertrofia: as faces ocultas da doença miocárdica
Speaker:
Maria Inês Vicente Soares
Congress:
CPC 2026
Topic:
K. Cardiovascular Disease In Special Populations
Theme:
30. Cardiovascular Disease in Special Populations
Subtheme:
30.14 Cardiovascular Disease in Special Populations - Other
Session Type:
Posters Eletrónicos
FP Number:
---
Authors:
Maria Inês Vicente Soares; Mariana Ramos; Rita Amador; Rui Gomes; Débora Correia; Tânia Laranjeira; Carlos Aguiar; Sérgio Maltês; Bruno Rocha
Abstract
<p>Introduction: <br /> Cardiac Amyloidosis (ATTR-CM) results from the deposition of wild-type (wtATTR-CM) or mutated/variant (hATTR-CM) transthyretin in the myocardium. Differentiating these subtypes is essential to guide targeted therapies, genetic counselling and family screening. </p> <p>Aims: </p> <p>To evaluate the temporal trends of genetic testing and the diagnostic yield in patients diagnosed with ATTR-CM. </p> <p>Methods: <br /> Single-center retrospective study including consecutive patients with ATTR-CM followed in a dedicated cardiomyopathy unit care, up to November 2025. Diagnosis of cardiac amyloidosis followed the recommended multi-step algorithm. Genetic testing for transthyretin variants was performed using next-generation sequencing (NGS), with confirmation by Sanger sequencing. All transthyretin (TTR) variants were classified according to ACMG guidelines. </p> <p>Results: <br /> A total of 304 patients with confirmed ATTR-CM were included, corresponding to a mean of 43 diagnoses per year (33 in 2019, 14 in 2020, 42 in 2021, 72 in 2022, 53 in 2023, 59 in 2024 and 31 in 2025). Of these, 196 patients (64%) underwent genetic testing (mean age of 82 ± 7 years, 80% male), corresponding to an average of 28 test requests per year. When analyzed per year, 15%, 43%, 39%, 43%, 43%, 59% and 64% of the cohort in 2019 to 2025, respectively, were genetically tested. The number of tests increased steadily from the start of the program (5 in 2019; 15 in both 2020 and 2021; 34 in 2022; 23 in 2023; 70 in 2024; 36 in 2025 – with 25 additional ongoing tests). </p> <p>Pathogenic TTR variants were identified in 21 patients (11%). These patients presented with a mean age of 73 ± 7 years (range 41–93). The most frequently identified variant was Val142Ile (n=13), followed by Val50Met (n=8). Compared with wtATTR-CM, those with hATTR-CM were significantly younger (73 ± 7 vs. 81 ± 6 years; p < 0.001). No significant differences were noted in cardiac disease severity at baseline. </p> <p>Most hATTR-CM patients presented firstly with cardiovascular manifestations, mainly heart failure (HF) (76%, n=16). Additionally, two patients presented with atrial fibrillation and other two with severe bradycardia requiring pacing. Extra-cardiac features varied by genotype: there was a higher burden of peripheral polyneuropathy in Val50Met carriers, whereas Val142Ile carriers generally showed minimal or mild extra-cardiac manifestations, with occasional subtle features (e.g., bilateral carpal tunnel syndrome). </p> <p>Conclusion: <br /> Genetic testing has progressively become part of the standard of care in ATTR-CM. We found a diagnostic yield of 11% in ATTR-CM population presenting primarily with HF. Our study supports the standardization of routine genetic testing, as the identification of hATTR-CM has direct implications for targeted therapies, cascade screening and follow-up of relatives. </p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site